Conditionally immortalised leukaemia initiating cells co-expressing Hoxa9/Meis1 demonstrate microenvironmental adaptation properties ex vivo while maintaining myelomonocytic memory
- PMID: 33674652
- PMCID: PMC7935976
- DOI: 10.1038/s41598-021-84468-3
Conditionally immortalised leukaemia initiating cells co-expressing Hoxa9/Meis1 demonstrate microenvironmental adaptation properties ex vivo while maintaining myelomonocytic memory
Abstract
Regulation of haematopoietic stem cell fate through conditional gene expression could improve understanding of healthy haematopoietic and leukaemia initiating cell (LIC) biology. We established conditionally immortalised myeloid progenitor cell lines co-expressing constitutive Hoxa9.EGFP and inducible Meis1.dTomato (H9M-ciMP) to study growth behaviour, immunophenotype and morphology under different cytokine/microenvironmental conditions ex vivo upon doxycycline (DOX) induction or removal. The vector design and drug-dependent selection approach identified new retroviral insertion (RVI) sites that potentially collaborate with Meis1/Hoxa9 and define H9M-ciMP fate. For most cell lines, myelomonocytic conditions supported reversible H9M-ciMP differentiation into neutrophils and macrophages with DOX-dependent modulation of Hoxa9/Meis1 and CD11b/Gr-1 expression. Here, up-regulation of Meis1/Hoxa9 promoted reconstitution of exponential expansion of immature H9M-ciMPs after DOX reapplication. Stem cell maintaining conditions supported selective H9M-ciMP exponential growth. H9M-ciMPs that had Ninj2 RVI and were cultured under myelomonocytic or stem cell maintaining conditions revealed the development of DOX-dependent acute myeloid leukaemia in a murine transplantation model. Transcriptional dysregulation of Ninj2 and distal genes surrounding RVI (Rad52, Kdm5a) was detected. All studied H9M-ciMPs demonstrated adaptation to T-lymphoid microenvironmental conditions while maintaining immature myelomonocytic features. Thus, the established system is relevant to leukaemia and stem cell biology.
Conflict of interest statement
The authors declare no competing interests.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7935976/bin/41598_2021_84468_Fig1_HTML.gif)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7935976/bin/41598_2021_84468_Fig2_HTML.gif)
![Figure 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7935976/bin/41598_2021_84468_Fig3_HTML.gif)
![Figure 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7935976/bin/41598_2021_84468_Fig4_HTML.gif)
![Figure 5](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7935976/bin/41598_2021_84468_Fig5_HTML.gif)
![Figure 6](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7935976/bin/41598_2021_84468_Fig6_HTML.gif)
![Figure 7](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7935976/bin/41598_2021_84468_Fig7_HTML.gif)
Similar articles
-
A Multiplex CRISPR-Screen Identifies PLA2G4A as Prognostic Marker and Druggable Target for HOXA9 and MEIS1 Dependent AML.Int J Mol Sci. 2021 Aug 30;22(17):9411. doi: 10.3390/ijms22179411. Int J Mol Sci. 2021. PMID: 34502319 Free PMC article.
-
Decoupling of tumor-initiating activity from stable immunophenotype in HoxA9-Meis1-driven AML.Cell Stem Cell. 2012 Feb 3;10(2):210-7. doi: 10.1016/j.stem.2012.01.004. Cell Stem Cell. 2012. PMID: 22305570 Free PMC article.
-
Hoxa9/meis1-transgenic zebrafish develops acute myeloid leukaemia-like disease with rapid onset and high penetrance.Open Biol. 2022 Oct;12(10):220172. doi: 10.1098/rsob.220172. Epub 2022 Oct 26. Open Biol. 2022. PMID: 36285442 Free PMC article.
-
The Historical Relationship Between Meis1 and Leukemia.Adv Exp Med Biol. 2022;1387:127-144. doi: 10.1007/5584_2021_705. Adv Exp Med Biol. 2022. PMID: 35304708 Review.
-
Deregulation of the HOXA9/MEIS1 axis in acute leukemia.Curr Opin Hematol. 2016 Jul;23(4):354-61. doi: 10.1097/MOH.0000000000000245. Curr Opin Hematol. 2016. PMID: 27258906 Free PMC article. Review.
References
-
- Stahlhut M, Schambach A, Kustikova OS. Multimodal lentiviral vectors for pharmacologically controlled switching between constitutive single gene expression and tetracycline-regulated multiple gene collaboration. Hum. Gene Ther. Methods. 2017;28:191–204. doi: 10.1089/hgtb.2017.073. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials